Loading…
Potentiation of N-Methyl-d-aspartate-Induced Currents by the Nootropic Drug Nefiracetam in Rat Cortical Neurons
Nefiracetam is a new pyrrolidone nootropic drug being developed for the treatment of Alzheimer's type and post-stroke vascular-type dementia. In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems has been found and is thought to play an...
Saved in:
Published in: | The Journal of pharmacology and experimental therapeutics 2003-10, Vol.307 (1), p.160-167 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Nefiracetam is a new pyrrolidone nootropic drug being developed for the treatment of Alzheimer's type and post-stroke vascular-type
dementia. In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems has
been found and is thought to play an important role in impairment of cognition, learning and memory. We have previously shown
that the activity of neuronal nicotinic acetylcholine receptors is potently augmented by nefiracetam. The present study was
undertaken to elucidate the mechanism of action of nefiracetam on glutamatergic receptors. Currents were recorded from rat
cortical neurons in long-term primary culture using the whole-cell patch-clamp technique at a holding potential of â70 mV
in Mg 2 + -free solutions. N -Methyl- d -aspartate (NMDA)-evoked currents were greatly and reversibly potentiated by bath application of nefiracetam resulting in
a bell-shaped dose-response curve. The minimum effective nefiracetam concentration was 1 nM, and the maximum potentiation
to 170% of the control was produced at 10 nM. Nefiracetam potentiation occurred at high NMDA concentrations that evoked the
saturated response, and in a manner independent of NMDA concentrations ranging from 3 to 1,000 μM. Glycine at 3 μM potentiated
NMDA currents but this effect was attenuated with an increasing concentration of nefiracetam from 1 to 10,000 nM. 7-Chlorokynurenic
acid at 1 μM prevented nefiracetam from potentiating NMDA currents. Nefiracetam at 10 nM shifted the dose-response relationship
for the 7-chlorokynurenic acid inhibition of NMDA currents in the direction of higher concentrations. α-Amino-3-hydroxy-5-methylisoxazole-4-propionic
acid- and kainate-induced currents were not significantly affected by application of 10 nM nefiracetam. It was concluded that
nefiracetam potentiated NMDA currents through interactions with the glycine binding site of the NMDA receptor. |
---|---|
ISSN: | 0022-3565 1521-0103 |
DOI: | 10.1124/jpet.103.050823 |